Related references
Note: Only part of the references are listed.CYP2C9*2 Allele Increases Risk for Hypoglycemia in POR*1/*1 Type 2 Diabetic Patients Treated with Sulfonylureas
G. Ragia et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2014)
No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population
E. Giannakopoulou et al.
MOLECULAR BIOLOGY REPORTS (2014)
Lack of Association of the P450 Oxidoreductase*28 Single Nucleotide Polymorphism with the Lipid-Lowering Effect of Statins in Hypercholesterolemic Patients
Georgia Ragia et al.
MOLECULAR DIAGNOSIS & THERAPY (2014)
Novel LDLR Variants in Patients with Familial Hypercholesterolemia: In Silico Analysis as a Tool to Predict Pathogenic Variants in Children and Their Families
Vasiliki Mollaki et al.
ANNALS OF HUMAN GENETICS (2013)
Effect of the P450 oxidoreductase *28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers
Jing-Jing Zhang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
NADPH-Cytochrome P450 Oxidoreductase: Roles in Physiology, Pharmacology, and Toxicology
David S. Riddick et al.
DRUG METABOLISM AND DISPOSITION (2013)
Drug Therapy of Hypercholesterolaemia in Children and Adolescents
Marjet J. A. M. Braamskamp et al.
DRUGS (2012)
Management of familial hypercholesterolaemia in children and adolescents
Robert N. Justo
JOURNAL OF PAEDIATRICS AND CHILD HEALTH (2012)
Statins Personalized
H. Robert Superko et al.
MEDICAL CLINICS OF NORTH AMERICA (2012)
Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3
Murali Subramanian et al.
PHARMACOGENETICS AND GENOMICS (2012)
Management of familial hypercholesterolemia in children and young adults: Consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization
O. S. Descamps et al.
ATHEROSCLEROSIS (2011)
Effects of the CYP Oxidoreductase Ala503Val Polymorphism on CYP3A Activity In Vivo: A Randomized, Open-Label, Crossover Study in Healthy Chinese Men
Guoping Yang et al.
CLINICAL THERAPEUTICS (2011)
Management of Familial Hypercholesterolemias in adult patients: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
Matthew K. Ito et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2011)
Pediatric aspects of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
Stephen R. Daniels et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2011)
The P450 oxidoreductase*28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients
Hylke de Jonge et al.
PHARMACOGENOMICS (2011)
Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro
Duanpen Sandee et al.
PHARMACOGENETICS AND GENOMICS (2010)
Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase
Vishal Agrawal et al.
PHARMACOGENETICS AND GENOMICS (2010)
The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test
Beatrice Oneda et al.
PHARMACOGENETICS AND GENOMICS (2009)
Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation
Ana M. Gomes et al.
PHARMACOGENOMICS (2009)
Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19
Vishal Agrawal et al.
PHARMACOGENETICS AND GENOMICS (2008)
Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin
J. -E. Park et al.
XENOBIOTICA (2008)
Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population
Kostas Arvanitidis et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2007)
Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase
Christa E. Flueck et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2007)
The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate
Dimitrios S. Christidis et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2006)
TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia
MF Mohrschladt et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2005)
Share Paper
